Elation Health vs Superluminal Medicines
Side-by-side comparison of AI visibility scores, market position, and capabilities
San Francisco primary care EHR for independent and DPC practices with physician-first clinical workflow design; $50M+ backed competing with athenahealth for 35,000+ independent primary care providers.
About
Elation Health is a San Francisco-based electronic health record (EHR) platform built specifically for primary care physicians and independent practices — providing a physician-designed clinical workflow system for internal medicine, family medicine, and pediatrics practices that prioritize direct patient relationships over corporate health system integration requirements. Founded in 2010 by Kyna Fong and backed with $50+ million raised from Kinnevik, Sapphire Ventures, and others, Elation Health serves 35,000+ primary care providers across independent practices, direct primary care (DPC) clinics, concierge medicine, and federally qualified health centers.
Boston AI GPCR drug discovery with $1.3B Eli Lilly collaboration Aug 2025 for obesity/cardiometabolic; $158M total ($120M RA Capital/Insight/NVIDIA/Lilly Series A Sep 2024) with MC4R obesity program advancing to IND competing with Relay Therapeutics.
About
Superluminal Medicines is a Boston-based biotechnology company — backed with approximately $158 million in total funding including a $33 million seed in 2023 and a $120 million Series A in September 2024 led by RA Capital Management with Insight Partners, NVIDIA's NVentures, and Eli Lilly — developing AI-driven small molecule drugs targeting G protein-coupled receptors (GPCRs), combining artificial intelligence, protein dynamics simulation, and structural biology to discover drugs for 70% of GPCRs that currently remain "undruggable" despite GPCRs representing the target class for approximately 35% of all FDA-approved drugs. In August 2025, Superluminal secured a landmark $1.3 billion collaboration agreement with Eli Lilly to discover small molecule therapeutics for obesity and cardiometabolic diseases, and is advancing its lead internal MC4R agonist program (for obesity treatment) toward IND-enabling studies with human trials expected Q4 2026. Founded in 2022.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.